Elsevier

Contraception

Volume 45, Issue 4, April 1992, Pages 313-324
Contraception

The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation

https://doi.org/10.1016/0010-7824(92)90053-VGet rights and content

Abstract

Children exposed to the injectable contraceptive Depo-Provera (DMPA) during pregnancy (N = 1,207), and/or during breastfeeding (N = 1,215) were compared to a control group composed of 1,167 children with no hormone exposures during pregnancy or breastfeeding. Weights and heights were measured for all children, and information on signs of puberty obtained for children aged ten and over. Cross-sectional weights and heights by age of DMPA-exposed children were similar to those for controls. Children with DMPA exposure during pregnancy and lactation had an increased risk of suboptimal growth in height, defined as less than two Z scores on NCHS standards (RR = 1.4, 95% CI 1.2–1.8). However, after adjustment for socioeconomic factors by multiple logistic regression, there was no increased risk of impaired growth among the DMPA-exposed children (RR = 1.1, 95% CI 0.8–1.6). With the exception of a delay in onset of reported pubic hair growth among DMPA-exposed girls, there were no significant effects on attainment of puberty. We conclude that use of DMPA during pregnancy or breastfeeding does not adversely affect the long-term growth and development of children.

References (12)

There are more references available in the full text version of this article.

Cited by (53)

  • Progestogen-only contraceptive use among breastfeeding women: a systematic review

    2016, Contraception
    Citation Excerpt :

    The literature search yielded 848 articles; 771 were excluded on title and abstract review and 28 were excluded after full-text review, leaving 49 reports meeting inclusion criteria. Since this review was last updated in 2008 [13], four new randomized controlled trials (RCTs) [20–23] and five new observational studies were published [16,24–27], and an additional five observational studies that were not included in the 2008 review were identified [28–32], for a total of eight reports of RCTs and 41 reports of nonrandomized clinical trials or observational studies for review (Table 1). These 49 articles reported on 47 different studies investigating the use of POCs in breastfeeding women and reported clinically relevant outcomes of infant growth, health or breastfeeding performance.

  • Canadian Contraception Consensus (part 3 of 4): Chapter 8 - Progestin-only contraception

    2016, Journal of Obstetrics and Gynaecology Canada
    Citation Excerpt :

    Un test de grossesse devrait être à nouveau mené de trois à quatre semaines plus tard. L’AMPR n’exerce pas d’effets tératogènes s’il est administré par mégarde en présence d’une grossesse188,189. Peu de médicaments interagissent avec l’AMPR.

View all citing articles on Scopus
View full text